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Background and aim: The Receptor Activity Modifying Proteins (RAMPs) are a group of accessory proteins, of
which there are three in humans, that interact with a number of G-protein coupled receptors (GPCR) and play
various roles in regulation of endocrine signaling. Studies in RAMP3 knockout (KO) mice reveal an age related
phenotype with altered metabolic regulation and high bone mass. To translate these ﬁndings into a clinically
relevant perspective, we investigated the association between RAMP3 gene variants, body composition and bone
phenotypes in two population-based cohorts of Swedish women.
Methods: Five single nucleotide polymorphisms (SNP) in the vicinity of the RAMP3 gene were genotyped in the
PEAK-25 cohort (n=1061; 25 years) and OPRA (n= 1044; 75 years). Bone mineral density (BMD), fat mass and
lean mass (total body; regional) were measured by DXA at baseline, 5 and 10 year follow-up.
Results: BMD did not diﬀer with RAMP3 genotype in either cohort, although fracture risk was increased in the
elderly women (OR 2.695 [95% CI 1.5144.801]). Fat mass tended to be higher with RAMP3 SNPs; although
only in elderly women. In the young women, changes in BMI and fat mass between ages 2535 diﬀered by
genotype (p=0.001; p < 0.001).
Conclusion: Variation in RAMP3 may contribute to age-related changes in body composition and risk of fracture.
1. Introduction
Osteoporosis is a common disease in our aging society, aﬀecting one
in three women during the course of their lifetime (Melton 3rd et al.,
1992). It is characterized by reduced bone mineral density (BMD), and
quantitative and qualitative changes to bone tissue, the clinical result of
which is an increased risk of fractures (Anonymous, 1993). An im-
portant determinant of future skeletal health is the attainment of peak
bone mass in young adulthood (Bonjour et al., 1994).
The maintenance of skeletal integrity through bone remodeling is
regulated by complex interactions between bone cells and endocrine
cells via a number of shared pathways (Karsenty and Oury, 2010; Pei
and Tontonoz, 2004). Osteoblasts and adipocytes share a common
progenitor, the pluripotent mesenchymal stem cell (Hu et al., 2018a),
with the balance between osteogenesis and adipogenesis changing with
age, resulting in a shift towards adipocytes (Berendsen and Olsen, 2014;
Chen et al., 2016). At the population level this is reﬂected in pro-
portionally higher fat mass, even without a change in body weight,
while the distribution of fat mass also changes with age (Prentice and
Jebb, 2001; Leal et al., 2015; Chantler et al., 2016).
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Given the mechanistic links between fat and bone metabolism, the
identiﬁcation of pleiotropic genes may oﬀer a deeper understanding of
the pathogenesis and underlying genetic architecture of osteoporosis
(Liu et al., 2009; Medina-Gomez et al., 2017; Hu et al., 2018b). In
contrast to the hypothesis-free approach of GWAS, the rationale for the
present candidate gene study is based on evidence from a mouse model,
for a high bone mass phenotype (Pacharne et al., 2011) and reduced
propensity to become obese with age (Dackor et al., 2007). This
knockout (KO) lacked the gene for an accessory protein receptor ac-
tivity modifying protein 3 (RAMP3) involved in signaling by the hor-
mones adrenomedullin and amylin.
Three mammalian RAMPs are known in humans. RAMPs are single-
pass transmembrane proteins, and an important family member of G
protein-coupled receptor (GPCR) accessory proteins (Hay et al., 2006;
Routledge et al., 2017). GPCRs recognize cell surface ligands to initiate
intracellular signaling (The state of GPCR Research in 2004, 2004) and
RAMPs modulate their pharmacology, traﬃcking and signaling prop-
erties. RAMPs were ﬁrst shown to interact with the calcitonin like-re-
ceptor (CLR), so that CLR+RAMP1 forms a receptor for calcitonin
gene-related peptide (CGRP) a peptide involved in pain perception and
vasodilator function. RAMPs 2 and 3 associate with the CLR to form two
distinct Adrenomedullin receptors. The CLR+RAMP2 Adrenome-
dullin-1 receptor (AM1R) is a potent vasodilator and has functions in
angiogenesis and a range of diseases. The CLR+RAMP3 Adrenome-
dullin-2 receptor (AM2R) is less well characterized. Interaction of
RAMP3 with the calcitonin receptor, produces an amylin receptor
complex (AMY3) (Routledge et al., 2017; The state of GPCR Research in
2004, 2004). RAMPs have also been show to interact with a number of
other GPCRs, and are predicted to have many more unknown partners
(Barbash et al., 2017).
Knockout of the various RAMPs in rodent models has established
distinct physiological functions throughout the life course. Targeted
deletion of RAMP3 demonstrated that it has an important role in reg-
ulating body weight with increased age; the mice lacking RAMP3 ap-
peared normal until reaching old age, after which time their weight
decreased (Dackor et al., 2007; Bailey et al., 2010). Furthermore, it has
also been shown that aging RAMP3 null mice have accelerated bone
development and higher bone mass compared with wild type controls.
Also, in response to mechanical loading, RAMP3 knockouts produce a
greater adaptive response as measured by more periosteal formation
(Livesey et al., 2013). This suggests that RAMP3 acts as a negative
modulator of bone adaptation, which can be explained in terms of
keeping bone mass to an appropriate level, and avoiding an over-en-
gineered skeleton which would be expensive to grow, maintain and use.
At the population level, human RAMP3 variants have not been studied
extensively, although functional characterization of two single nu-
cleotide polymorphisms (SNPs) in the human RAMP3 protein has been
performed (Bailey et al., 2010).
The rationale for our study was to comprehensively evaluate the
association between selected RAMP3 SNPs with bone and body com-
position phenotypes in the setting of a prospective study design. We
hypothesized that RAMP3 variants would be associated with 1) body
composition, 2) change in body composition and 3) bone phenotypes
including fracture. Moreover, we also explore 4) age related diﬀerences
in the contribution of RAMP3 SNPs to these phenotypes in two diﬀer-
ently aged cohorts of women; young adults and elderly women.
2. Materials and methods
2.1. Subjects
Two population based cohorts of Swedish women were studied; the
OPRA (Osteoporosis Prospective Risk Assessment) cohort consisting of
1044 elderly women all aged exactly 75 (75.2 ± 0.1) at the time of
recruitment and the PEAK-25 cohort consisting of 1061 women all aged
exactly 25 years (25.5+ 0.2).
The OPRA cohort was prospectively followed with reassessment at
5 years (n=715) and 10 years (n= 382); the PEAK-25 cohort returned
for assessment after 10 years (n= 731).
Informed consent was obtained from all individual participants in-
cluded in the study and all procedures performed were in accordance
with the ethical standards of the Regional Ethical Review Board in Lund
and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards.
2.2. Measurement of BMD and body composition using DXA
BMD and body composition were measured using dual-energy x-ray
absorptiometry (OPRA: Lunar DPX-L; PEAK-25: Lunar Prodigy (Lunar
Corporation, Madison, WI, USA)). BMD (g/cm2) was measured at the
Lumbar spine (LS), femoral neck (FN) and total body (TB). Lumbar
spine from OPRA participants was not included in the analyses in due to
the high incidence of degenerative changes (Tenne et al., 2013). Body
composition measures included fat mass (FM, kg) and lean mass (LM,
kg) measured at total body (TB), trunk and leg.
Calibrations were performed daily using a phantom supplied by the
manufacturer. Precision error for bone density at baseline was 0.94%
and 1.45% for total body and lumbar spine respectively in the OPRA
cohort (Lenora et al., 2010) and 0.90% and 0.65% for femoral neck and
lumbar spine respectively in PEAK-25 (Callreus et al., 2012).
Coeﬃcients of variation for body composition were 30.2% and
10.6% for total body fat and total body lean mass respectively in OPRA;
and 39.6% and 11.6% respectively in PEAK-25. For the OPRA cohort,
all measurements at baseline were performed using the same instru-
ment, while analyses of scans were made with software versions 1.33
and 1.35. For PEAK-25, the same instrument was used throughout, with
software versions 2.157.70.
Additional phenotypes measured included weight (kg); height (cm)
and BMI (kg\m2). The ratio between fat mass and lean mass was cal-
culated, for total body and trunk fat.
2.3. Fracture
In young women fracture incidence is low; therefore, fracture data is
analyzed only in OPRA. Information on fractures was continuously re-
gistered through the X-rays ﬁles at the Radiology Department, Malmö,
Skåne University Hospital, as previously described in detail (Buchebner
et al., 2014). This department serves the Department of Orthopedics,
the only unit treating adult and pediatric fractures in the catchment
area, hence loss to follow-up is low (Jonsson et al., 1994). Prevalent
fractures (i.e., prior to inclusion in the study at age 75) were registered,
as previously reported (Gerdhem and Akesson, 2007).
In the current analyses however we report only on incident fracture
data collected until October 31, 2012, providing a maximum follow-up
for fracture of 17.2 years (mean 13.1 years). Fractures resulting from
pathology and high energy trauma were excluded. In this report, our
primary outcomes were any fracture, major osteoporotic fracture
(i.e., hip, vertebra, distal radius, and shoulder) and hip fracture as a
group and per fracture.
2.4. Blood sample collection and genotyping
Non-fasting blood was collected before noon for DNA isolation and
stored at -800c until analysis. Total genomic DNA was isolated using the
QIAamp 96 DNA blood kit (Qiagen, Valencia, CA, USA).
2.5. Genotyping
Five SNPs in and around the RAMP3 gene (Chromosome 7p13) were
genotyped in both cohorts (Table 1). SNPs were selected from ensembl
(http://www.ensembl.org).
Genotyping was performed using Taqman SNP genotyping Assay
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(Applied Biosystems, Foster City, CA, USA). PCR was conducted in a
Dual 384-well GeneAmp PCR system 9700, with an endpoint plate read
on ABI 7900HT using the SDS 2.2.2 software (Applied Biosystems).
Genotyping was performed blind and approximately 3% of samples
from each cohort were genotyped in duplicate with 100% concordance.
DNA was available for 1004 (OPRA) and 1006 (PEAK-25) individuals.
Genotyping was successful in 997 to 1002 women (OPRA) and 999 to
1002 women (PEAK-25); an overall success rate of> 98%. Departures
from Hardy-Weinberg equilibrium (HWE) were tested for each SNP
using the Chi2 test with one degree of freedom (HWE Program, Jurg Ott
and Rockefeller University, New York). All SNPs followed HWE
(p≥ 0.05).
2.6. Statistical analysis
Genotype speciﬁc diﬀerences between phenotypes were analyzed
with the Kruskal-Wallis test using dominant models (comparing the
major allele homozygotes Vs. heterozygotes + minor allele homo-
zygotes) and recessive models (comparing the major allele homo-
zygotes + heterozygotes allele Vs. minor allele homozygotes).
Regression analysis was performed to determine association between
SNPs and phenotypes, adjusting for confounders as appropriate (body
size (i.e. Height2), TBFM, BMD, smoking). The Chi2 test was used to
analyze association between genotypes and categorical variables (e.g.
fracture); while linear regression was used to identify and adjust for
confounding factors. Age was not adjusted for since all participants
within each cohort were the same age. A priori power analyses, as-
suming a SD of 0.13 g/cm2 in BMD, indicated that our sample size al-
lowed>80% power to detect diﬀerences of 0.065 g/cm2 between
genotypes assuming a minor allele frequency of> 0.21.
The phenotypes and markers studied are not fully independent
therefore applying a Bonferroni correction would be over-stringent. We
report uncorrected p-values (two-tailed), acknowledging that multiple
tests were performed. Nominal signiﬁcance was considered with
p < 0.05. Statistical analysis was performed with SPSS (v20.0, SPSS
Inc., Chicago, IL).
3. Results
RAMP3 genotype and minor allele frequencies did not diﬀer be-
tween the cohorts (Table 2). The general and clinical characteristics of
the participants from the two diﬀerently aged cohorts of women are
reported in Table 3. As expected, in comparison to the elderly OPRA
participants, the young PEAK-25 women had higher lean mass and
lower fat mass values. This is reﬂected by a higher ratio of fat to lean
mass -overall and at the trunk, in the older women.
3.1. Association of RAMP3 SNPs with body composition
We observed age related diﬀerences between RAMP3 SNPs and the
phenotypes studied. In OPRA, carriers of SNP rs2074654 minor C' al-
lele tended towards slightly higher values of both fat (TB-FM 2.21%
diﬀerence), and lean mass (TB-LM 1.34%), although after adjustment
for body size, p-values increased at some sites (Table 4). The ratio of fat
to lean mass did not diﬀer. In the PEAK-25 cohort, after adjustment for
body size, body composition did not diﬀer with RAMP3 genotype (data
not shown).
3.2. Association of RAMP3 SNPs with change in body composition
We investigated whether RAMP3 SNPs were associated with change
in body composition over time; over 5-years for the elderly women and
10-years in the young women. In the elderly women, changes in body
composition, between the ages of 7580, did not diﬀer with genotype
for any of the SNPs (Supplementary Table S1).
In contrast, in the young PEAK-25 cohort, changes in BMI and fat
mass over 10-years i.e. between ages 25 and 35 diﬀered with genotype.
Individuals carrying the minor A' allele of SNP rs3757575 increased
with respect to BMI, overall fat mass and trunk adiposity and the ratio
of fat to lean mass also increased. Lean mass however did not diﬀer
appreciably with genotype (Table 5).
3.3. Association of RAMP3 SNPs with skeletal phenotypes
In the elderly women, risk of any type of fracture was higher among
carriers of the minor C' allele of SNP rs2074654 independent of bone
density and fat mass (ORadjusted 2.695 [95% CI 1.5144.801].
Osteoporotic fracture risk was also elevated, although only after ad-
justment, while hip fracture did not diﬀer (Table 6).
In the OPRA cohort, BMD did not diﬀer with rs2074654 genotype at
any measured site (FN: 0.763 Vs 0.785, p= 0.22) nor with the other
studied SNPs or with change in BMD between the ages of 7580 (data
not shown). In the PEAK-25 cohort, after adjustment for body size, no
diﬀerences in bone density or with change in BMD between ages 25 and
35 (data not shown) were observed.
4. Discussion
The objective of the present study was to determine the association
between RAMP3 variants with body composition, bone density and
fracture. The basis for the study lies in the manifestation of a bone and
body composition phenotype, which diﬀered with age, in a knockout
mouse model (Pacharne et al., 2011) and the assumption that key
regulatory genes are shared across species. In this candidate gene as-
sociation study we speciﬁcally wanted to address the temporal aspect
and determine if association diﬀered at young and old age and ad-
ditionally whether RAMP3 genotype was related to change in these
phenotypes over 5 or 10 years of aging.
Results from the study tentatively suggest that RAMP3 SNPs may
play a role, albeit minor, in regulating body composition and inﬂuence
fracture risk. We found that levels of both fat and lean mass diﬀered
with variation in RAMP3, although only in the elderly women. Given
that the cohorts were similarly sized, we assume that this lack of re-
plication is not a question of study power, but rather reﬂects an age
dependent relationship. This is supported by observations from other
studies that the eﬀect size of weight susceptibility genes diﬀers across
the life course (Kvaloy et al., 2013). We also observed that in the young
women change in fat mass diﬀered with RAMP3 variation; carriers of
the common allele gaining less fat overall and at the trunk (i.e. main-
taining a leaner phenotype). In very old age, there was no genotype
related diﬀerence in change-in-fat-mass over the ﬁve years studied. We
reason that this possibly is because at older ages environmental and
lifestyle factors along with overall health status have a stronger impact
than genetic factors in maintaining a stable weight. This is in line with
the reduced predictability with advancing age also noted for speciﬁc
biomarkers. Although the mechanisms underlying the results of this
present study are unclear, in an animal study (Dackor et al., 2007)
Dackor et al. reported that RAMP3 plays an important role in main-
taining normal body weight with age. The results of the present study
Table 1
RAMP3 SNPs genotyped in this study.
SNP (Major/Minor
Alleles)
Position (in chromosomal
order)
Description
rs3757575 (G/A) Chr 7: 45156136 Upstream; intergenic
rs2074654 (T/C) Chr 7: 45177416 Exon 2; non-synonymous
(missense)
rs1294935 (T/C)a Chr 7: 45178767 Intron 2; tag SNP
rs11982639 (C/G) Chr 7: 45183419 3UTR; splice site
rs12702121 (A/G) Chr 7: 45183660 Exon 3; tag SNP
a Minor allele in Ensembl is T.
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seem to support this ﬁnding. We speculate that RAMPs act to mediate
the basal eﬀects of normal GPCR signaling, and that under physiolo-
gical conditions or disease RAMP3 may become induced to alter the
signaling of GPCRs (Kvaloy et al., 2013; Hewitt et al., 2005; Gibbons
et al., 2007; Ono et al., 2000).
Contrary to our hypothesis that variation in the RAMP3 gene could
be associated with bone density, because of the interdependence with
body weight and fat mass, bone density did not diﬀer between geno-
types at any age. Despite this, risk of fracture in the elderly women
increased, apparently independently of BMD and fat mass. This may
mirror factors not measured with the techniques used, such as quali-
tative aspects of cortical and trabecular bone. Alternatively, through
eﬀects on muscle function by GPCR (White, 2016) which might lead to
falls. Association with osteoporosis related phenotypes is feasible. There
are a number of functionally-relevant RAMP3 variants in humans and in
our study rs3757575 is an upstream intergenic SNP that may aﬀect
transcription while rs2074654 is exonic, non-synonymous and has the
potential to alter gene expression. Indeed, this latter SNP, despite its
low frequency is predicted to be deleterious, based on disruption of the
protein structure or interference with its function or interaction (Bailey
et al., 2010; Burke et al., 2007). Typically, in such cases risk of devel-
oping the disease can be increased even if not itself causal. It should
also be kept in mind that there may be species diﬀerences in the roles of
RAMP3, both in relation to speciﬁc modulation of a single GPCR in-
teracting partner and in the relative changes induced by the complex
interactions of RAMP3 with all its partners. Dissection of these complex
relationships is out with the scope of this study.
Limitations of this study are acknowledged, the ﬁrst being that this
is a candidate gene approach and the reported associations modest at
best. Although GWAS has been very successful in identifying loci, the
majority as yet have no proven biological role in bone metabolism,
while this study was hypothesis driven, based on functional evidence of
a bone-body composition phenotype from an animal model. The
stronger eﬀects observed in the animal models, possibly reﬂect that a
knock-out of the gene provides more extreme phenotypes and/or that
mice over 1 year old are not a perfect model for aged humans. Secondly,
Table 2
RAMP3 genotype frequencies in the PEAK-25 and OPRA cohorts.
SNP & Alleles PEAK-25 OPRA
Homozygotes Major
Allele
No. (%)
Heterozygotes
No. (%)
Homozygotes Minor
Allele
No. (%)
MAF Homozygotes Major
Allele
No. (%)
Heterozygotes
No. (%)
Homozygotes Minor
Allele
No. (%)
MAF
rs3757575 (G/A) 592
(59.3%)
365
(36.5%)
42
(4.2%)
0.23 622
(62.3%)
334
(33.4%)
43
(4.3%)
0.21
rs2074654 (T/C) 905
(90.3%)
93
(9.3%)
4
(0.4%)
0.05 933
(93.2%)
65
(6.5%)
3
(0.3%)
0.04
rs1294935 (T/C) 260
(26.0%)
484
(48.4%)
255
(25.5%)
0.50 234
(23.4%)
496
(49.7%)
268
(26.9%)
0.48
rs11982639 (C/G) 594
(59.4%)
340
(34.0%)
66
(6.6%)
0.24 617
(61.9%)
332
(33.3%)
48
(4.8%)
0.21
rs12702121 (A/G) 595
(59.4%)
341
(34.0%)
66
(6.6%)
0.24 619
(61.8%)
334
(33.3%)
49
(4.9%)
0.22
Table 3
Anthropometric and clinical characteristics of the OPRA and PEAK-25 cohorts
at baseline.
Variable N PEAK-25 N OPRA
Age (yrs) 1060 25.5 (0.20) 1044 75.23 (0.15)
Weight (kg) 1060 64.7 (11.40) 1044 67.78 (11.68)
Height (cm) 1060 167.6 (6.08) 1024 160.52 (5.71)
BMI (kg/m2) 1060 23.04 (3.81) 1024 26.27 (4.12)
Current/former smoker 1060 457 (43.4%) 1044 354 (33.9%)
BMD (g/cm2)
Femoral neck 1058 1.053 (0.123) 947 0.765 (0.138)
Total hip Not available 924 0.849 (0.149)
Total body 1060 1.174 (0.073) 931 1.006 (0.098)
Lumbar spine 1060 1.239 (0.131) 976 0.884 (0.170)
Body Composition (kg)
Total Body - Fat mass 1060 21.22 (8.40) 931 26.09 (7.90)
Total Body - Lean mass 1060 40.38 (4.68) 931 37.28 (3.95)
Total Body - Ratio Fat/Lean 1060 0.53 (0.19) 931 0.70 (0.19)
Trunk - Fat mass 1060 10.22 (4.65) 931 12.57 (3.93)
Trunk - Lean mass 1060 19.71 (2.48) 931 19.00 (2.18)
Trunk - Ratio Fat/Lean 1060 0.52 (0.21) 931 0.66 (0.18)
Values are mean (standard deviation).
Table 4
Association of RAMP3 rs2074654 with BODY COMPOSITION in elderly women (OPRA cohort).
OPRA
Variable at Baseline (75 yrs)
rs2074654 TT Homozygotes (n= 842) rs2074654C Allele Carriers
(n=61)
Diﬀerence P-valuea P-valueb
(adjusted)
Fat Mass (kg)
Total body 25.96 (0.28) 28.17 (0.82) 2.21 0.024 0.065
Trunk 12.50 (0.14) 13.73 (0.41) 1.23 0.018 0.035
Leg 9.06 (0.11) 9.75 (0.31) 0.69 0.035 0.147
Lean mass (kg)
Total body 37.23 (0.14) 38.57 (0.54) 1.34 0.015 0.041
Trunk 18.98 (0.08) 19.60 (0.28) 0.62 0.029 0.117
Leg 12.03 (0.05) 12.60 (0.21) 0.57 0.011 0.038
Ratio Fat\Lean mass
Total body 0.70 (0.01) 0.73 (0.02) 0.30 0.129 0.144
Trunk 0.70 (0.01) 0.73 (0.02) 0.03 0.129 0.144
Leg 0.75 (0.01) 0.78 (0.02) 0.03 0.163 0.275
Association analyzed using the dominant model (comparing major allele homozygotes Vs. heterozygotes+minor allele homozygotes). Reported values, mean (SE).
a Kruskal-Wallis.
b Linear regression - adjusted for body size.
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not all phenotypes were available in both cohorts, i.e. fractures in
young women were not included due to low prevalence. Thirdly, we
cannot generalize if the results are applicable to other ages, ethnicities
or men. In particular, RAMP3 expression is potently regulated by es-
trogen, and contains functional estrogen receptor response elements in
its promoter (Watanabe et al., 2006), hence further studies in women
around menopause and at other time points thereafter, in other large
cohorts would be of interest.
Strengths of the study include the comprehensive and extensive
body composition and bone data collected in both cohorts, and the
design of the cohorts - each containing approximately one thousand
women with a homogeneous origin and residency, thus limiting po-
tential bias from population stratiﬁcation and environmental exposures.
The single age of each cohort also minimizes confounding. This design,
and the long duration of follow-up, allows investigation of temporal
changes at diﬀerent time windows in an eﬀort to understand the con-
tribution of genetic variation to bone health during the life-course.
Furthermore, selection of RAMP3 variants is based on a biological ra-
tional and identiﬁcation of a phenotype in an animal model assuming
shared pathways, rather than from GWAS; and the SNP's studied,
broadly encompass the gene region.
We conclude that polymorphisms in the RAMP3 gene may con-
tribute to the age-associated changes of body composition and risk of
fracture, however needing further exploration of the underlying me-
chanisms.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.gene.2019.100009.
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